These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34451981)

  • 41. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
    Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
    Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial.
    Lin L; Parra MM; Sierra VY; Cespedes AS; Granados MA; Luque A; Damaso S; Castrejon Alba MM; Romano-Mazzotti L; Struyf F
    Pediatr Infect Dis J; 2018 Apr; 37(4):e93-e102. PubMed ID: 29424799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High HPV vaccination uptake rates for adolescent girls after regional governmental funding in Shiki City, Japan.
    Hayashi Y; Shimizu Y; Netsu S; Hanley S; Konno R
    Vaccine; 2012 Aug; 30(37):5547-50. PubMed ID: 22749837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: Results of the Nagoya study.
    Suzuki S; Hosono A
    Papillomavirus Res; 2018 Jun; 5():96-103. PubMed ID: 29481964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and perception: What are the greatest enemies of HPV vaccination programmes?
    Bonanni P; Zanella B; Santomauro F; Lorini C; Bechini A; Boccalini S
    Vaccine; 2018 Aug; 36(36):5424-5429. PubMed ID: 28610824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The controversy on HPV vaccination in Japan: Criticism of the ethical validity of the arguments for the suspension of the proactive recommendation.
    Okita T; Enzo A; Kadooka Y; Tanaka M; Asai A
    Health Policy; 2020 Feb; 124(2):199-204. PubMed ID: 31924344
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial.
    Stratton P; Battiwalla M; Tian X; Abdelazim S; Baird K; Barrett AJ; Cantilena CR; Childs RW; DeJesus J; Fitzhugh C; Fowler D; Gea-Banacloche J; Gress RE; Hickstein D; Hsieh M; Ito S; Kemp TJ; Khachikyan I; Merideth MA; Pavletic SZ; Quint W; Schiffman M; Scrivani C; Shanis D; Shenoy AG; Struijk L; Tisdale JF; Wagner S; Williams KM; Yu Q; Wood LV; Pinto LA
    JAMA Oncol; 2020 May; 6(5):696-705. PubMed ID: 32105293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
    Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
    Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Compensation programs after withdrawal of the recommendation for HPV vaccine in Japan.
    Yuji K; Nakada H
    Hum Vaccin Immunother; 2016 May; 12(5):1321-4. PubMed ID: 26513303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
    Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
    JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Community-based household assessment of human papillomavirus (HPV) vaccination coverage and acceptability - HPV vaccine demonstration program, Cambodia - 2017.
    Garon J; Wuddhika IV; Sreenivasan N; Wannemuehler K; Vutthikol Y; Chhorvann C; Loharikar A
    Vaccine; 2019 Feb; 37(9):1202-1208. PubMed ID: 30686637
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors influencing uptake of HPV vaccination among girls in Germany.
    Schülein S; Taylor KJ; König J; Claus M; Blettner M; Klug SJ
    BMC Public Health; 2016 Sep; 16():995. PubMed ID: 27645711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of Texas physicians.
    Kahn JA; Cooper HP; Vadaparampil ST; Pence BC; Weinberg AD; LoCoco SJ; Rosenthal SL
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2325-32. PubMed ID: 19661092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.
    Lin L; Macias Parra M; Sierra VY; Salas Cespedes A; Granados MA; Luque A; Karkada N; Castrejon Alba MM; Romano-Mazzotti L; Borys D; Struyf F
    Pediatr Infect Dis J; 2019 Oct; 38(10):1061-1067. PubMed ID: 31469776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database.
    Héquet D; Pouget N; Estevez JP; Robain M; Rouzier R
    Bull Cancer; 2015 Nov; 102(11):892-7. PubMed ID: 26526386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence and predictors of human papillomavirus vaccination in adolescent girls.
    Palli SR; Mehta S; Aparasu RR
    J Am Pharm Assoc (2003); 2012; 52(1):52-8. PubMed ID: 22257616
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
    Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A
    Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adverse events following HPV vaccination, Alberta 2006-2014.
    Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML
    Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.